Johnson & Johnson Innovative Medicine
NDC Database

Johnson & Johnson Innovative Medicine

NDC Database

National Drug Code (NDC) records including drug products, NDC numbers, nonproprietary names, dosage forms, strengths, labelers and marketing information.

Drug for Further Processing
  • Total Records 18
  • Latest Marketing Date 2018-02-14
  • Data Source FDA
  • First Marketing Date 2008-03-08
Company Overview

Company

Johnson & Johnson Innovative Medicine

Country

U.S.A

Website

Visit Website

Email

Social Profiles

Company Snapshot

Johnson & Johnson Innovative Medicine

1125 Trenton-Harbourton Road, P.O. Box 200, Titusville, NJ 08560

U.S.A

www.janssen.com/us/ View on Map
NDC Records ( 18 records )
2018
14 Feb
Drug for Further Processing NDC: 17314-215

Nonproprietary Name

apalutamide

Dosage Form

TABLET, FILM COATED

Strength

60 mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-215

Substance

APALUTAMIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2018-02-14

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
08 Aug
Drug for Further Processing NDC: 17314-315

Nonproprietary Name

canagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED

Strength

50; 500 mg/1; mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-315

Substance

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-08-08

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
08 Aug
Drug for Further Processing NDC: 17314-317

Nonproprietary Name

canagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED

Strength

50; 1000 mg/1; mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-317

Substance

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-08-08

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
08 Aug
Drug for Further Processing NDC: 17314-320

Nonproprietary Name

canagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED

Strength

150; 500 mg/1; mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-320

Substance

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-08-08

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2014
08 Aug
Drug for Further Processing NDC: 17314-322

Nonproprietary Name

canagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED

Strength

150; 1000 mg/1; mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-322

Substance

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2014-08-08

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
20 Sep
Drug for Further Processing NDC: 17314-515

Nonproprietary Name

canagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

50; 500 mg/1; mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-515

Substance

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-09-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
20 Sep
Drug for Further Processing NDC: 17314-517

Nonproprietary Name

canagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

50; 1000 mg/1; mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-517

Substance

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-09-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
20 Sep
Drug for Further Processing NDC: 17314-520

Nonproprietary Name

canagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

150; 500 mg/1; mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-520

Substance

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-09-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
20 Sep
Drug for Further Processing NDC: 17314-522

Nonproprietary Name

canagliflozin and metformin hydrochloride

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

150; 1000 mg/1; mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-522

Substance

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-09-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
20 Sep
Drug for Further Processing NDC: 17314-575

Nonproprietary Name

canagliflozin

Dosage Form

TABLET, FILM COATED

Strength

100 mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-575

Substance

CANAGLIFLOZIN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-09-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2016
20 Sep
Drug for Further Processing NDC: 17314-577

Nonproprietary Name

canagliflozin

Dosage Form

TABLET, FILM COATED

Strength

300 mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-577

Substance

CANAGLIFLOZIN

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2016-09-20

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
27 Apr
Drug for Further Processing NDC: 17314-603

Nonproprietary Name

darunavir ethanolate

Dosage Form

TABLET, FILM COATED

Strength

150 mg/1

Labeler

JANSSEN ORTHO LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-603

Substance

DARUNAVIR ETHANOLATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2009-04-27

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2009
14 Jan
Drug for Further Processing NDC: 17314-605

Nonproprietary Name

darunavir ethanolate

Dosage Form

TABLET, FILM COATED

Strength

400 mg/1

Labeler

JANSSEN ORTHO LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-605

Substance

DARUNAVIR ETHANOLATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2009-01-14

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2008
08 Mar
Drug for Further Processing NDC: 17314-607

Nonproprietary Name

darunavir ethanolate

Dosage Form

TABLET, FILM COATED

Strength

600 mg/1

Labeler

JANSSEN ORTHO LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-607

Substance

DARUNAVIR ETHANOLATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2008-03-08

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2012
09 Nov
Drug for Further Processing NDC: 17314-609

Nonproprietary Name

darunavir ethanolate

Dosage Form

TABLET, FILM COATED

Strength

800 mg/1

Labeler

JANSSEN ORTHO LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-609

Substance

DARUNAVIR ETHANOLATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2012-11-09

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2008
01 Oct
Drug for Further Processing NDC: 17314-705

Nonproprietary Name

Cetirizine Hydrochloride

Dosage Form

TABLET, FILM COATED

Strength

5 mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-705

Substance

CETIRIZINE HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2008-10-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2008
01 Oct
Drug for Further Processing NDC: 17314-737

Nonproprietary Name

Cetirizine Hydrochloride

Dosage Form

TABLET, FILM COATED

Strength

10 mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-737

Substance

CETIRIZINE HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2008-10-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
31 Jan
Drug for Further Processing NDC: 17314-812

Nonproprietary Name

darunavir ethanolate and cobicistat

Dosage Form

TABLET, FILM COATED

Strength

150; 800 mg/1; mg/1

Labeler

Janssen Ortho LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

17314-812

Substance

COBICISTAT; DARUNAVIR ETHANOLATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-01-31

End Marketing Date

-

Listing Record Certified Through

2026-12-31

Related Databases
  • FDA Inspections
    7 View
  • EDQM CEP
    46 View
  • KDMF
    0 View
  • Japan DMF
    0 View
  • Eudra GMP
    0 View
  • NDC Database
    18 View
  • FDA Approved Drugs Database
    154 View
  • Drug Prices in Switzerland
    0 View
NDC Type Breakdown
18 total
  • Drug for Further Processing
Official Source

NDC data is based on publicly available National Drug Code information from the U.S. Food and Drug Administration (FDA).

Visit FDA NDC Directory
NDC Record Details Preview

Explore important National Drug Code information available in the records above.

NDC

17314-215

Nonproprietary Name

apalutamide

Labeler

Janssen Ortho LLC

Dosage Form

TABLET, FILM COATED

FDA NDC Data

National Drug Code information

Regular Updates

Data maintained from official sources

Structured Database

Searchable pharmaceutical data

Reliable Data

Organized NDC records

NDC data is based on publicly available U.S. Food and Drug Administration (FDA) National Drug Code information.

Create a New Buying Request

Fields marked with * are mandatory.

Please enter quantity.
Please select a unit.
Please select quality standard.
Please select request type.
Please provide product specifications.
Please enter additional details.
Please select shipping preference.
Notice: By submitting this buying request, the provided product details and requirements may be published publicly on our marketplace.
Login to Submit